<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043989</url>
  </required_header>
  <id_info>
    <org_study_id>J16144</org_study_id>
    <secondary_id>IRB00117591</secondary_id>
    <nct_id>NCT03043989</nct_id>
  </id_info>
  <brief_title>Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin</brief_title>
  <official_title>Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maryland Technology Development Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is being conducted to recommend a safe and tolerable phase 2 dose of&#xD;
      docetaxel or cabazitaxel when combined with clarithromycin in men who have developed&#xD;
      castrate-resistant prostate cancer.&#xD;
&#xD;
      In the castrate-resistant setting, resistance to taxane therapy inevitably develops. Men who&#xD;
      develop resistance to taxanes have a very poor prognosis, and few treatment options.&#xD;
&#xD;
      It is believed that CYP enzymes contribute to docetaxel and cabazitaxel resistance in&#xD;
      metastatic prostate cancer, and this resistance can be mitigated through pharmacologic CYP&#xD;
      inhibition. In this study a potent CYP3A inhibitor, clarithromycin, will be co-administered&#xD;
      concurrently with either docetaxel or cabazitaxel, whose systemic metabolism is dependent of&#xD;
      CYP3A4, with the intent to overcome resistance to taxanes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-escalation study designed to determine the maximum tolerated dose of docetaxel&#xD;
      or cabazitaxel when given in combination with clarithromycin. Eligible patients will be&#xD;
      assigned to docetaxel or cabazitaxel, based on which drug they were previously administered&#xD;
      prior to study entry. Enrollment to dose levels will be in a 3+3 cohort design until the&#xD;
      maximum tolerated dose is achieved.&#xD;
&#xD;
      Docetaxel or cabazitaxel will be administered on day 1 of each (3 week) cycle for a total of&#xD;
      6 cycles. Subjects in both arms will be administered clarithromycin on days -1, 1 and 2 of&#xD;
      each 3 week cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Actual">July 26, 2019</completion_date>
  <primary_completion_date type="Actual">July 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Escalate dose up the maximum tolerated dose achieved, and initiate this as the recommended phase 2 dose of docetaxel and of cabazitaxel when it is combined with clarithromycin.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare docetaxel OR cabazitaxel exposure (maximal [Cmax] when combined with the strong CYP3A4 inhibitor clarithromycin to historic controls.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare docetaxel OR cabazitaxel exposure ( total [AUC]) when combined with the strong CYP3A4 inhibitor clarithromycin to historic controls.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel and clarithromycin combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.&#xD;
Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabazitaxel and clarithromycin combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.&#xD;
Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>6 infusions of Docetaxel with 18 doses clarithromycin</description>
    <arm_group_label>Docetaxel and clarithromycin combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>6 infusions of Cabazitaxel with 18 doses clarithromycin</description>
    <arm_group_label>Cabazitaxel and clarithromycin combination</arm_group_label>
    <other_name>JEVTANA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>18 doses of clarithromycin with either Docetaxel or Cabazitaxel</description>
    <arm_group_label>Cabazitaxel and clarithromycin combination</arm_group_label>
    <arm_group_label>Docetaxel and clarithromycin combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men with metastatic castrate-resistant prostate cancer (prostate cancer progressing&#xD;
             despite castrate levels of testosterone &lt;50 ng/dL), using standard measures of&#xD;
             progression defined by PCWG2&#xD;
&#xD;
          2. Have received at least 4 cycles of docetaxel or cabazitaxel, and less than ten, with&#xD;
             two consecutive rising PSA values, checked at least 7 days apart. No PSA decline in&#xD;
             last 42 day&#xD;
&#xD;
          3. Bone disease documented by either: a positive bone scan, CT scan, or MRI; or&#xD;
             biopsy-proven bony metastases&#xD;
&#xD;
          4. Age ≥18 years&#xD;
&#xD;
          5. ECOG performance status ≤ 2 (Karnofsky ≥ 60%)&#xD;
&#xD;
          6. Have normal organ and marrow function defined as:&#xD;
&#xD;
               -  absolute neutrophil count ≥1,500/mcL&#xD;
&#xD;
               -  platelets ≥100,000/mcL&#xD;
&#xD;
               -  total bilirubin (within normal institutional limits)&#xD;
&#xD;
               -  AST/ALT ≤ 2.5 × ULN (or ≤ 1.5 x ULN in conjunction with alk phos &gt;2.5 x ULN for&#xD;
                  Docetaxel&#xD;
&#xD;
               -  AST ≤ 1.5 x ULN for Cabazitaxel&#xD;
&#xD;
               -  creatinine clearance-no minimum for Docetaxel&#xD;
&#xD;
               -  creatinine clearance- ≥ 30 mL/min/1.73 m2 for Cabazitaxel&#xD;
&#xD;
          7. No evidence of clinical progression, in the form of increased lesions on&#xD;
             cross-sectional imaging, or new cancer-attributable symptoms or worsening of existing&#xD;
             symptoms&#xD;
&#xD;
          8. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have residual toxicities &gt; Grade 2 attributed to taxane therapy, except&#xD;
             for neuropathy, who are excluded if &gt; grade 1&#xD;
&#xD;
          2. Patients who are receiving any other investigational agents or have within the last 28&#xD;
             day.&#xD;
&#xD;
          3. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to clarithromycin or taxanes&#xD;
&#xD;
          4. Patients receiving any medications or substances that are inhibitors or inducers of&#xD;
             CYP3A4 are ineligible&#xD;
&#xD;
          5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          6. Received more than 10 cycles of docetaxel [for docetaxel cohort only] or 6 of&#xD;
             cabazitaxel [for cabazitaxel cohort only]&#xD;
&#xD;
          7. Last docetaxel or cabazitaxel dose &gt; 6 weeks prior to enrollment&#xD;
&#xD;
          8. Patients with a documented history of QT prolongation or ventricular cardiac&#xD;
             arrhythmia, including torsades de pointes, or taking drugs that are known to prolong&#xD;
             the QT&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Carducci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 26, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>docetaxel</keyword>
  <keyword>cabazitaxel</keyword>
  <keyword>phase 1b</keyword>
  <keyword>castration-resistant</keyword>
  <keyword>bone metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

